OncoMed racks up three straight clinical disasters as lead drug implodes
OncoMed $OMED just added a fresh page to its nightmare story on cancer drug development.
Following up recent back-to-back clinical failures, the biotech says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
